Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its position in Edwards Lifesciences Co. (NYSE:EW) by 176.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,221 shares of the medical research company’s stock after acquiring an additional 24,398 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Edwards Lifesciences were worth $2,830,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences in the third quarter worth about $32,000. Avior Wealth Management LLC boosted its stake in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the period. Finally, JFS Wealth Advisors LLC raised its position in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,489 shares of company stock worth $2,002,829. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 0.8 %

Shares of NYSE EW opened at $72.72 on Tuesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a market cap of $42.89 billion, a price-to-earnings ratio of 10.43, a P/E/G ratio of 4.82 and a beta of 1.11. The business has a fifty day simple moving average of $72.83 and a 200-day simple moving average of $70.13.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Truist Financial restated a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Citigroup boosted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.